Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.975 USD | -3.99% | +13.86% | +88.86% |
01:05pm | Baird Downgrades Geron to Neutral From Outperform, Price Target at $4.50 | MT |
Apr. 29 | TD Cowen Initiates Geron With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.86% | 2.44B | |
-3.23% | 102B | |
+1.32% | 96.29B | |
+2.13% | 22.18B | |
-15.78% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-14.60% | 16.36B | |
+4.55% | 13.97B | |
+32.23% | 12.17B |
- Stock Market
- Equities
- GERN Stock
- News Geron Corporation
- Geron's Imetelstat's Safety a Key Focus for FDA's Oncology Drugs Advisory Committee Meeting